Literature DB >> 6319219

Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease.

P Sharon, W F Stenson.   

Abstract

Leukotriene B4, an arachidonic acid metabolite, is a potent chemotactic agent, and is thought to be an important mediator of inflammation. To investigate the role of this compound as a mediator of inflammation in inflammatory bowel disease, arachidonic acid was incubated with ionophore and colonic mucosa from patients with inflammatory bowel disease and from normal subjects. Mucosa from patients with inflammatory bowel disease converted 2.17% of exogenous arachidonate to leukotriene B4; mucosa from normal subjects converted 0.37%. The production of leukotriene was blocked by sulfasalazine. To determine if inflammatory bowel mucosa contained endogenous leukotriene B4, lipid extracts were analyzed by high pressure liquid chromatography. Mucosa from patients with inflammatory bowel disease contained 254 ng of leukotriene B4 per gram and mucosa from normal subjects contained less than 5 ng of leukotriene B4 per gram. The presence of significant amounts of leukotriene B4 in colonic mucosa in patients with inflammatory bowel disease, combined with the known biologic effects of leukotriene B4, suggests that it may be an important mediator of inflammation in inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6319219

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  197 in total

1.  A chronic ulcerative colitis model in rats.

Authors:  Li Zheng; Zhen-Qiang Gao; Shu-Xian Wang
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

Review 2.  A lay doctor's guide to the inflammatory process in the gastrointestinal tract.

Authors:  S Pathmakanthan; C J Hawkey
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

3.  Temporal changes in colonic vascular architecture and inflammatory mediator levels in animal models of colitis.

Authors:  Caroline B Appleyard; Adrian Alvarez; William H Percy
Journal:  Dig Dis Sci       Date:  2002-09       Impact factor: 3.199

4.  Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial.

Authors:  A B Hawthorne; T K Daneshmend; C J Hawkey; A Belluzzi; S J Everitt; G K Holmes; C Malkinson; M Z Shaheen; J E Willars
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

Review 5.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

Review 6.  Immediate and long range effects of the uptake of increased amounts of arachidonic acid.

Authors:  O Adam
Journal:  Clin Investig       Date:  1992-09

7.  Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis.

Authors:  Hiroyuki Hanai; Ken Takeuchi; Takayuki Iida; Nobuhito Kashiwagi; Abby R Saniabadi; Isao Matsushita; Yoshihiko Sato; Naoki Kasuga; Toshihiro Nakamura
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

8.  Effect of a leukotriene B4 receptor antagonist on leukotriene B4-induced neutrophil chemotaxis in cavine dermis.

Authors:  D J Fretland; D L Widomski; J M Zemaitis; S W Djurić; R L Shone
Journal:  Inflammation       Date:  1989-10       Impact factor: 4.092

9.  The effect of leukotriene-B4 receptor antagonist, SC-41930, on acetic acid-induced colonic inflammation.

Authors:  D J Fretland; S Levin; B S Tsai; S W Djurić; D L Widomski; J M Zemaitis; R L Shone; R F Bauer
Journal:  Agents Actions       Date:  1989-06

10.  Modulation of human colonic arachidonic acid metabolism by sulfasalazine.

Authors:  C J Hawkey; N K Boughton-Smith; B J Whittle
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.